Predilife S.A. (ALPRE.PA)
Predilife S.A. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Villejuif, IF, FR. The stock last traded at $1.49, up 15.95% on the session, giving a market capitalisation of $5.9M. Its beta of 0.25 implies it has historically moved less than the broad market.
Founded in 2004 and headquartered in Villejuif, France, Predilife S.A. specializes in devising and commercializing sophisticated medical technologies and analytical models. The company's core offerings include preventative healthcare solutions and comprehensive breast screening tests. Among its notable products are MammoRisk, a diagnostic tool designed to forecast an individual's risk of developing breast cancer; DenSeeMammo, software for evaluating breast tissue density; and a specialized medical device developed for predicting prostate cancer risk.
Predilife S.A. is most often compared with the following Healthcare names: